HOME >> BIOLOGY >> NEWS
Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus

Presented at Amer. Assoc. for the Study of Liver Diseases Conference

BOULDER, Colorado, November 9, 1998 -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) today announced that HEPTAZYME®, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was effective in decreasing Hepatitis C Viral RNA in cell culture assays. This work was presented at the American Association for the Study of Liver Diseases (AASLD) conference in Chicago by Dr. Lawrence Blatt, RPI's Senior Director of Biopharmacology and Preclinical Research. In these studies, HEPTAZYME® demonstrated significant inhibition of the HCV viral translation process in cells at very low doses, and in a manner that implies applicability across multiple forms of the virus.

Hepatitis C Virus (HCV) is the most common chronic bloodborne infection in the United States today. A recent Centers for Disease Control report stated that over 4 million Americans are chronically infected with HCV, and it is estimated that 500 million people are infected with HCV worldwide. The disease, which is more common than HIV, kills 8,000-10,000 Americans annually, and the death toll is expected to triple over the next 10-20 years. Furthermore, development of effective treatments has been hampered by the presence of multiple forms of HCV, with at least six genotypes and more than 90 subtypes known.

HEPTAZYME® contains many novel features believed to be important for HCV treatment. First, HEPTAZYME® is a ribozyme, a catalytic RNA molecule that has the unique potential to bind and cleave HCV RNA specifically and selectively, thus suggesting that viral replication can be inhibited without affecting other normal physiological processes. Next, HEPTAZYME® cleaves the HCV RNA at a location that is completely conserved in all known genotypes and subtypes of HCV, which gives HEPTAZYME® the potential to inhibit all forms of the virus. Finally, since HCV replicates in the cytoplas
'"/>

Contact: Neil Cohen
neil@noonanrusso.com
415-677-4455 x. 205
Noonan/Russo Communications
9-Nov-1998


Page: 1 2 3

Related biology news :

1. Ribozyme package effective against hepatitis B virus
2. Ribozymes Come Ready For Action
3. Ribozymes To The Rescue: New UF Gene Therapy Shows Promise For Treatment Of Inherited Blindness
4. Interdisciplinary Method Offers New Way To Study Ribozymes
5. Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors
6. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
7. Study Demonstrates High Conservation Potential Of Logged Rainforest
8. Potential for enhanced sequestration of carbon in soils supports evaluations
9. Potent toxin reveals new antibiotic resistance mechanism
10. Potential blood test for colon cancer risk
11. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/4/2017)... , Oct. 4, 2017  GCE Solutions, a global clinical research ... and document anonymization solution on October 4, 2017. Shadow is designed ... to comply with policy 0070 of the European Medicines Agency (EMA) ... ... Solutions ...
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/30/2017)... June 30, 2017 Today, American Trucking ... supplier of face and eye tracking software, became ... provider program. "Artificial intelligence and ... to monitor a driver,s attentiveness levels while on ... able to detect fatigue and prevent potential accidents, ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... will be hosting a Webinar titled, “Pathology is going digital. Is your lab ... digital pathology adoption best practices and how Proscia improves lab economics and realizes ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer ... first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. , With ... with the challenge of how to continue to feed a growing nation. At the ...
Breaking Biology Technology:
Cached News: